News Releases

August 9, 2021
Global rights to registrational-stage ophthalmology drug return to Molecular Partners Improvements in manufacturing and formulation have been made and tested in  pre-clinical models with the potential to overcome inflammatory side effects Ongoing research discovery alliance with AbbVie in
July 8, 2021
Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern EMPATHY Phase 2/3 trial enrolling ambulatory patients in 5 countries with more countries to be added in the coming months, with
Displaying 31 - 36 of 36
* These releases may contain price sensitive information